By Michael Borella — This first five or so weeks of 2018 have been busy for Federal Circuit 35 U.S.C. § 101 jurisprudence. At last count, four substantive decisions have come down so far (including this one, but not including Rule 36 judgments without opinion). Out of these, two have found the claims at issue to be patent-eligible, and one has found the claims to be ineligible. This case splits the baby, finding some claims ineligible and others in need of further review. But the impact of today's decision may be further-reaching than the other three. At the very least,…Original Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.